#USA #Providence #Mayo Clinic #OncoLux #optical theranostics

OncoLux Enters a New Era in Optical Theranostics with Mayo Clinic Collaboration

OncoLux Inc., based in Providence, Rhode Island, has announced a pivotal agreement with the Mayo Clinic to advance its groundbreaking optical theranostics technology. This innovative approach aims to enhance the field of robotic bronchoscopy by integrating advanced optical diagnostics and therapy delivery mechanisms, furthering the commitment to improve cancer treatment outcomes.

Robotic bronchoscopy systems have recently gained attention for their ability to expedite both the diagnosis and treatment process for lung cancer, a disease where timely intervention is crucial. By employing these systems, medical professionals can conduct minimally invasive biopsies of suspicious lung nodules, which are often precursors to lung cancer. The collaboration with the Mayo Clinic will leverage their extensive clinical expertise to expedite the development of OncoLux's technology, ensuring it effectively augments the capabilities of existing robotic systems.

Dr. Alan Kersey, CEO of OncoLux, expressed his enthusiasm about the partnership, stating, "We are excited and honored to collaborate with Mayo Clinic, a world-leading institution dedicated to addressing unmet needs in surgical care. Our joint efforts will focus on optimizing the application of our optical theranostics platform to benefit patients suffering from lung cancer."

The Innovative Technology

OncoLux's optical theranostics platform stands out for combining multispectral fluorescence imaging with photodynamic therapy, allowing for superior visualization during surgeries. This technology aims to not only diagnose but also treat cancer in real time. The multispectral fluorescence technology possesses the remarkable capability to see beyond the conventional limits of human sight, enabling surgeons to precisely identify and map malignant tissues during procedures.

The collaboration will also investigate approaches for delivering therapeutic solutions directly at the cancer site using the photodynamic therapy approach that OncoLux is pioneering. This combination could potentially alter the standard of care for patients facing lung cancer, through enhanced accuracy in locating tumors and delivering treatment in a minimally invasive manner.

Robotic Bronchoscopy's Importance

Robotic bronchoscopy serves as a critical tool in the fight against lung cancer, facilitating quick biopsies that can contribute to faster diagnosis and treatment initiation. The implementation of robotic systems allows for flexible catheter delivery via an endotracheal tube, reaching all segments of the lung while offering a platform for integrating OncoLux's technology to deliver both diagnosis and therapy seamlessly.

The integration aims to transform current biopsy protocols, drastically reducing diagnosis time while simultaneously providing the opportunity for immediate treatment - embodying the concept of 'See and Treat' in an intraoperative setting.

Future Endeavors

This collaboration is scheduled to commence in early 2026, with investigative contributions from Dr. Janani S. Reisenauer and Dr. Matthew J. Aizpuru of the Mayo Clinic. Their expertise will guide the application of OncoLux's innovative technologies in a clinical setting, striving to enhance the prognosis for lung cancer patients by addressing time-sensitive treatment needs.

Furthermore, Mayo Clinic will maintain a financial interest in the developments stemming from this agreement, with any revenue generated directed toward supporting its charitable mission in patient care, research, and education.

About OncoLux

OncoLux is at the forefront of advancing optical theranostics with a mission to develop technologies that can improve surgical outcomes for cancer patients. Their focus on integrating advanced photonics and artificial intelligence into surgical practices marks a substantial shift in medical technology aimed at minimizing invasiveness while maximizing efficacy. With a team of seasoned professionals and a steadfast commitment to innovation, OncoLux is poised to make meaningful contributions to the field of oncology and beyond. For more information about OncoLux, please visit OncoLux Inc..